Fusion Pharmaceuticals Inc (FUSN) Stock: What Does the Chart Say Friday?

Fusion Pharmaceuticals Inc (FUSN) stock is higher by 9.25% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Fusion Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FUSN!

See Full FUSN Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With FUSN Stock Today?

Fusion Pharmaceuticals Inc (FUSN) stock has gained 3.33% while the S&P 500 has fallen -0.48% as of 3:37 PM on Friday, Dec 9. FUSN has gained $0.08 from the previous closing price of $2.40 on volume of 41,344 shares. Over the past year the S&P 500 has fallen -16.09% while FUSN has fallen -54.91%. FUSN lost -$1.85 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Fusion Pharmaceuticals Inc click here.

More About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. Click Here to get the full Stock Report for Fusion Pharmaceuticals Inc stock.